Search results
Curis reports progress in leukemia study with expanded patient dataset By Investing.com
Investing.com· 4 days agoCuris, Inc. (NASDAQ: CRIS), a biotechnology company, has announced an expansion of its dataset in an...
Curis Announces Additional Data from TakeAim Leukemia Study
WRBL Columbus· 4 days agoCuris, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced updated data from ...
Ryvu Therapeutics First Quarter 2024 Financial Results and Corporate Update
NBC 17 Raleigh· 3 days agoAs of May 9, 2024, Ryvu's cash position was $59.0M, inclusive of the first tranche of €8M in venture debt from the EIB, obtained in March. This cash position, and other secured funding sources ...
EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for...
CBS 47 Fresno· 2 days agoAscentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the ...
Anti-diabetic treatment associated with reduced risk of developing blood cancer
Medical Xpress· 19 hours agoA meta-analysis of previous studies connected the therapy with a reduction in the risk of...
Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to...
Nature· 4 days agoIn contrast to B-cell precursor acute lymphoblastic leukemia (ALL), molecular subgroups are less well defined in T-lineage ALL. Comprehensive studies on molecular T-ALL subgroups ...
Half-matched family donors offer best outcomes for Hispanic patients undergoing bone marrow...
Medical Xpress· 3 days agoThe study retrospectively assessed outcomes from 88 patients with B-cell ALL (an aggressive type of ...
The gray area of RQ-PCR-based measurable residual disease: subdividing the “positive, below...
Nature· 1 day agoDetection of measurable residual disease (MRD) in hematological malignancies is crucial for prognostication and treatment decisions. Real-time quantitative PCR (RQ-PCR), which targets immunoglobulin ...
Patients Over 80 Still Benefit From Treatment for AML Blood Cancer
Alaska Superstation· 4 days agoSeniors over 80 with acute myeloid leukemia can safely and effectively take the standard targeted...
Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
Zacks via Yahoo Finance· 17 hours agoThe median overall survival in the study was 14.3 months, with 40% of patients responding to...